Latham & Watkins Advises Biomea Fusion in US$56 Million Series A Financing

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, has announced the closing of a US$56 million Series A financing. The syndicate is led by Cormorant Asset Management with participation from Boxer Capital of Tavistock Group, Janus Henderson Investors, Rock Springs Capital, RTW Investments LP, Aisling Capital, Point Sur Investors, Logos Capital and Clifton Capital.

Latham & Watkins LLP represents Biomea Fusion, Inc. in the financing with a corporate deal team led by Bay Area partners Miles Jennings, and Brian Cuneo, with associates Valerie Lau and Adam Zuckerman. Advice was also provided on tax matters by Bay Area partner Ashley Wagner.